CD33 and leukemia: On iMSC, the leukemia blasts lose the expression of the myeloid marker CD33+ (myelo-suppressive) while on iANG the blasts retain the expression of CD33 with the emergence of a population of CD15+ cells (myelo-permissive) (Figures S3I and S3J; Key resources table).